MedTrace Logo

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

NCT06908707 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-11-17

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women

Conditions

  • Postmenopausal
  • Healthy Adult Female Participants

Interventions

DRUG

LAE102 SC

A single dose of LAE102 will be administered subcutaneously

DRUG

Placebo SC

A single dose of placebo administered subcutaneously

DRUG

LAE102 IV

A single dose of LAE102 administered intravenously

DRUG

Placebo IV

A single dose of placebo administered intravenously

Sponsors & Collaborators

Principal Investigators

  • Dr. Hugh Coleman, MD · Fortrea Clinical Research Unit Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-22
Primary Completion
2025-10-23
Completion
2025-10-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06908707 on ClinicalTrials.gov